⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

GRANULES - Technical Analysis with Chart Patterns & Indicators

← Back to List

⭐ Rating: 3.2

Last Updated Time : 02 Aug 26, 01:49 pm

Key Parameters

⭐ Technical Rating: 3.2

Stock CodeGRANULES
Market Cap20,442 Cr.
Current Price825 ₹
High / Low910 ₹
Stock P/E50.7
Book Value178 ₹
Dividend Yield0.21 %
ROCE12.8 %
ROE10.5 %
Face Value1.00 ₹
DMA 50811 ₹
DMA 200683 ₹
Chg in FII Hold2.19 %
Chg in DII Hold-0.90 %
PAT Qtr71.8 Cr.
PAT Prev Qtr99.0 Cr.
RSI43.7
MACD6.36
Volume7,26,264
Avg Vol 1Wk8,29,260
Low price433 ₹
High price910 ₹
PEG Ratio-7.93
Debt to equity0.19
52w Index82.2 %
Qtr Profit Var-8.70 %
EPS16.5 ₹
Industry PE33.6

✅ Positive

Granules India recently achieved debt-free status, a significant positive for its financial health and future growth prospects. Analyst reports suggest bullish sentiment following recent results, indicating potential upside.

⚠️ Limitation

The stock exhibits volatility with a relatively high P/E ratio of 50.7, suggesting it may be overvalued compared to industry peers. Fluctuations in institutional holding percentages (FII and DII) could impact short-term price movements.

📉 Company Negative News

Recent news highlights the company's transition towards peptide CDMO targets, but also points out a -8.70% quarter-on-quarter profit variance which might indicate underlying pressures. Furthermore, one report suggests analysts are bullish, however this does not guarantee any specific movement for the stock.

📈 Company Positive News

Granules India has successfully become debt-free in Q1FY27, demonstrating strong financial management and improving its balance sheet. Analyst reports suggest optimism regarding future performance based on recent results.

🏭 Industry

The pharmaceutical ingredients industry is currently experiencing moderate growth driven by increasing demand for generic drugs and contract manufacturing services (CDMO). While competitive pressures exist, companies with a diversified product portfolio and strong R&D capabilities are well-positioned for success.

🧾 Conclusion

Based on the current chart patterns and indicators, the stock appears to be consolidating around the 825 ₹ level. An optimal entry zone could be between 790 ₹ (support) and 840 ₹ (resistance). Exit strategies should target resistance at 910 ₹ or consider a move towards 770 ₹ if the RSI exceeds 60, indicating potential overbought conditions. The stock’s overall trend remains neutral pending further price action.

Technical Analysis
Fundamental Analysis

NIFTY 50 · Technical

NEXT 50 · Technical

MIDCAP · Technical

SMALLCAP · Technical